Metoprolol: A review of its use in chronic heart failure

Drugs

Volumn 60, Issue 3, 2000, Pages 647-678

  Prakash, A ^a   Markham, A ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

BISOPROLOL; CARVEDILOL; CELIPROLOL; INHIBITORY GUANINE NUCLEOTIDE BINDING PROTEIN; LOPRESSOR SR; METOPROLOL; METOPROLOL TARTRATE;

ARTICLE; ATRIOVENTRICULAR BLOCK; BETA ADRENERGIC RECEPTOR BLOCKING; BRADYCARDIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; DRUG MECHANISM; DRUG TOLERABILITY; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOTENSION; META ANALYSIS; QUALITY OF LIFE; RECEPTOR DENSITY;

ANGINA;

EID: 0033778598     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200060030-00011     Document Type: Article

References (96)

1. The effect of digoxin on mortality and morbidity in patients with heart failure
2. Digoxin and mortality in chronic heart failure
3. Consensus recommendations for the management of chronic heart failure
4. Mild systolic dysfunction in heart failure (left ventricular ejection fraction >35%): Baseline characteristics, prognosis and response to therapy in the Vasodilator in Heart Failure Trials (V-HeFT)
5. Effects of neurohormonal antagonism on symptoms and quality-of-life in heart failure
6. Mechanism of action of beta-blocking agents in heart failure
7. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure
8. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure
9. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): A randomised trial
10. Metoprolol: An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in hypertension, ischaemic heart disease and related cardiovascular disorders
11. The role of beta-blockers in left ventricular dysfunction and heart failure
12. Pathophysiologic and pharmacologic rationales for clinical management of chronic heart failure with betablocking agents
13. The cellular and physiologic effects of beta blockers in heart failure
14. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group
15. Effect of metoprolol on myocardial function and energetics in patients with non-ischemic dilated cardiomyopathy: A randomized, double-blind, placebo-controlled study
16. Changes in early and late diastolic filling patterns induced by long-term adrenergic β-blockade in patients with idiopathic dilated cardiomyopathy
17. Heart rate dependency of cardiac performance in heart failure patients treated with metoprolol
18. Early reduction in plasma norepinephrine during beta-blocking therapy with metoprolol in chronic heart failure
19. Time course of improvement in left ventricular function, mass and geometry in patients with congestive heart failure treated with beta-adrenergic blockade
20. Exercise hemodynamics and myocardial metabolism during long-term beta-adrenergic blockade in severe heart failure
21. Safety and efficacy of beta blockade in patients with chronic congestive heart failure awaiting transplantation
22. Effects of metoprolol on rest and exercise cardiac function and plasma catecholamines in chronic congestive heart failure secondary to ischemic or idiopathic cardiomyopathy
23. Beta-blockers for heart failure: Is slowing of heart rate essential
24. More favourable haemodynamic effects from metoprolol than from captopril in patients with dilated cardiomyopathy
25. Combined alpha-beta blockade (doxazosin plus metoprolol) compared with beta blockade alone in chronic congestive heart failure
26. Short-term and long-term hemodynamic and clinical effects of metoprolol alone and combined with amlodipine in patients with chronic heart failure
27. β blockers in heart failure: A comparison of a vasodilating β blocker with metoprolol
28. Prospective, randomized comparison of effect of long-term treatment with metoprolol or carvedilol on symptoms, exercise, ejection fraction, and oxidative stress in heart failure
29. Differential effects of β-blockers in patients with heart failure: A prospective, randomized, double-blind comparison of the long-term effects of metoprolol versus carvedilol
30. Hemodynamic comparison of twice daily metoprolol tartrate with once daily metoprolol succinate in congestive heart failure
31. Improvement of exercise capacity and left ventricular diastolic function with metoprolol XL after acute myocardial infarction
32. Effect of controlled-release metoprolol on blood pressure and exercise heart rate in hypertension: A comparison with conventional tablets
33. Efficacy and tolerability of a new controlled-release formulation of metoprolol: A comparison with conventional metoprolol tablets in mild to moderate hypertension
34. Pharmacokinetic and pharmacodynamic properties of a new controlled-release formulation of metoprolol: A comparison with conventional tablets
35. The effect on heart rate of immediate and slow-release metoprolol in patients with chronic heart failure
36. Effects of metoprolol CR in patients with ischemic and dilated cardiomyopathy: The Randomized Evaluation of Strategies for Left Ventricular Dysfunction Pilot Study
37. Metoprolol CR/XL in patients with heart failure: A pilot study examining the tolerability, safety, and effect on left ventricular ejection fraction
38. Effect of β-blockade on left ventricular function and natriuretic peptides in patients with chronic heart failure treated with angiotensin-converting enzyme inhibitor
39. Long-term effects of heart rate reduction in patients with heart failure: Comparison with chronic β-adrenergic blockade
40. Randomised trial of low-dose amiodarone in severe congestive heart failure
41. Non-sustained ventricular tachycardia in congestive heart failure and β-blocker therapy
42. QT dispersion in congestive heart failure and effects of chronic beta-blocker therapy (Merit-HF pilot study)
43. Improvement in QT-dispersion with selective vs. non-selective β-blockade in patients with dilated cardiomyopathy
44. A sustained increase in β-adrenoceptors during long-term therapy with metoprolol and bisoprolol in patients with heart failure from idiopathic dilated cardiomyopathy
45. Effect of metoprolol on the β-adrenoceptor density of lymphocytes in patients with dilated cardiomyopathy
46. Effects of metoprolol on myocardial β-adrenoceptors and G(iα)-proteins in patients with congestive heart failure
47. Comparative hemodynamic, left ventricular functional, and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart
48. Beneficial effects of metoprolol treatment in congestive heart failure: Reversal of sympathetic-induced alterations of immunologic function
49. Left ventricular systolic function and lymphocyte beta-adrenoreceptor density in congestive heart failure patients treated by metoprolol
50. Design of a new multiple-unit controlled-release formulation of metoprolol -metoprolol CR
51. Controlled release metoprolol: Clinical pharmacokinetics and therapeutic implications
52. Enhancement of the bioavailability of propranolol and metoprolol by food
53. Metoprolol metabolism via cytochrome P4502D6 in ethnic populations
54. The oxidative metabolism of metoprolol in human liver microsomes: Inhibition by the selective serotonin uptake inhibitors
55. Pharmacokinetics of metoprolol enantiomers in Chinese subjects of major CYP2D6 genotypes
56. Comparison of CYP2D6 content and metoprolol oxidation between microsomes isolated from human livers and small intestines
57. Pharmacokinetic and pharmacodynamic comparison of a new controlled-release formulation of metoprolol with a traditional slow-release formulation
58. Pharmacokinetics and pharmacodynamics of controlled-release metoprolol: A comparison with atenolol
59. 1-blockade in healthy subjects: A study on conventional metoprolol and metoprolol CR/ZOK formulations
60. β-Adrenoceptor blockade in congestive heart failure: Future perspectives
61. Recovery from left ventricular asynergy in ischemic cardiomyopathy following long-term beta blockade treatment
62. Beneficial effects of metoprolol in heart failure associated with coronary artery disease: A randomized trial
63. Beta-blockade in heart failure: A comparison of carvedilol with metoprolol
64. 3-year follow-up of patients randomised in the metoprolol in dilated cardiomyopathy trial
65. Effect of metoprolol on the prognosis for patients with suspected acute myocardial infarction and indirect signs of congestive heart failure (a subgroup analysis of the Goteborg Metoprolol Trial)
66. Quality of life on treatment with metoprolol in dilated cardiomyopathy: Results from the MDC trial. Metoprolol in Dilated Cardiomyopathy trial
67. Carvedilol appears to reduce mortality in patients with advanced chronic heart failure
68. Combined oral positive inotropic and beta-blocker therapy for treatment of refractory class IV heart failure
69. Meta-analysis of effect of beta-blockade on mortality in NYHA class IV CHF patients
70. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)
71. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: The Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF)
72. Rationale, design, and organization of the Metoprolol CR/XL Randomized Intervention Trial in Heart Failure (MERTI-HF)
73. The mortality effect of metoprolol CR/XL in patients with heart failure: Results of the MERIT-HF trial
74. Metoprolol succinate and metoprolol tartrate
75. Congestive heart failure: Epidemiology and cost of illness
76. Economics of treating heart failure
77. ABC of heart failure: Acute and chronic management strategies
78. Effects of betablocker therapy on mortality in patients with heart failure. A systematic overview of randomized controlled trials
79. Effect of beta-blockade on mortality in patients with heart failure: A meta-analysis of randomized clinical trials
80. Clinical effects of β-adrenergic blockade in chronic heart failure: A meta-analysis of double-blind, placebo-controlled, randomized trials
81. β-adrenergic blocking agents in heart failure: Benefits of vasodilating and nonvasodilating agents according to patients' characteristics: A meta-analysis of clinical trials
82. Benefit of β-blockers for heart failure: Proven in 1999
83. The evidence for β blockers in heart failure: Equals or surpasses that for angiotensin converting enzyme inhibitors
84. β-adrenergic blockade in chronic heart failure
85. ABC of heart failure. Management: Digoxin and other inotropes, β blockers, and antiarrhythmic and antithrombotic treatment
86. Experience with beta blockers in heart failure mortality trials
87. β-blocker therapy for heart failure. The evidence is in, now the work begins
88. Drug treatment in heart failure
89. Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease
90. Bucindolol fails in BEST trial
91. What type of β-blocker should be used to treat chronic heart failure
92. Are all β-blockers for heart failure the same?
93. Are all β-blockers for heart failure the same?
94. COMET: A multicentre randomised double-blind study to compare the effect of carvedilol and metoprolol on morality and morbidity in patients with moderate or severe congestive heart failure (NYHA II-IV)
95. β-blockers in heart failure: The 'new wave' of clinical trials